Amela Biosciences AG
Designed cell matrices for reproducible in vitro biology
Most cell matrices used in 3D cell culture and biofabrication are animal-derived and poorly defined, leading to batch variability, limited reproducibility, and inconsistent outcomes. This slows research, reduces comparability across laboratories, and limits industrial adoption of advanced in vitro models. Emerging validation requirements for in vitro models further increase need for defined, reproducible materials. Amela Biosciences develops animal-free, recombinant protein-based cell matrices with defined composition and tunable properties. Originating from ETH Zurich and ZHAW, the technology is protected by exclusive patents. The team combines expertise in protein design, biotechnology, and business. The market for advanced cell matrices is projected to exceed USD 1 billion by 2030.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
No news
No milestones
No Jobs
No videos and documents
Venture Kick
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
Amela Biosciences AG
Designed cell matrices for reproducible in vitro biology
Website:
www.amelabiosciences.com
Headquarter:
St. Gallen
Foundation Date:
June 2026
Technology:
- Biotech
Sectors:
- 3D Printing
- Applications
- Biomaterials
- Biotech
- Cosmetics
- Diagnostics
- Drug discovery
- Food
Support received
